ECSP10010395A - Formulacion de capsula - Google Patents

Formulacion de capsula

Info

Publication number
ECSP10010395A
ECSP10010395A EC2010010395A ECSP10010395A ECSP10010395A EC SP10010395 A ECSP10010395 A EC SP10010395A EC 2010010395 A EC2010010395 A EC 2010010395A EC SP10010395 A ECSP10010395 A EC SP10010395A EC SP10010395 A ECSP10010395 A EC SP10010395A
Authority
EC
Ecuador
Prior art keywords
pharmaceutically active
liquid
ingredient
solid
capsule formulation
Prior art date
Application number
EC2010010395A
Other languages
English (en)
Inventor
Yoshihiro Uchiyama
Tomohiro Yoshinari
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of ECSP10010395A publication Critical patent/ECSP10010395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

RESUMENLa presente invención proporciona la siguiente preparación de cápsula, que es superior en la característica de disolución y similares de un ingrediente farmacéuticamente activo y contiene los ingredientes farmacéuticamente activos líquidos y sólidos: una cápsula transparente que contiene los ingredientes farmacéuticamente activos líquidos y sólidos, en donde el ingrediente líquido farmacéuticamente activo se encapsula en forma de composición farmacéutica líquida, y el ingrediente sólido farmacéuticamente activo se dispersa en una capa de cubierta de cápsula.
EC2010010395A 2008-01-10 2010-08-10 Formulacion de capsula ECSP10010395A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008003634 2008-01-10

Publications (1)

Publication Number Publication Date
ECSP10010395A true ECSP10010395A (es) 2010-09-30

Family

ID=40853060

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010395A ECSP10010395A (es) 2008-01-10 2010-08-10 Formulacion de capsula

Country Status (21)

Country Link
US (1) US20100285121A1 (es)
EP (3) EP2229939A4 (es)
JP (1) JP5421126B2 (es)
KR (1) KR20100111292A (es)
CN (3) CN101969932A (es)
AU (1) AU2008345848B2 (es)
BR (1) BRPI0822019A2 (es)
CA (1) CA2711814A1 (es)
CO (1) CO6290641A2 (es)
CR (1) CR11625A (es)
DO (3) DOP2010000214A (es)
EA (3) EA201200830A1 (es)
EC (1) ECSP10010395A (es)
IL (1) IL206791A0 (es)
MA (1) MA32027B1 (es)
MX (1) MX2010007609A (es)
MY (1) MY157189A (es)
NZ (3) NZ600720A (es)
UA (3) UA102477C2 (es)
WO (1) WO2009087938A1 (es)
ZA (1) ZA201004793B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
WO2010119319A1 (en) 2009-03-09 2010-10-21 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a free fatty acid, and methods and uses thereof
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
EP3318255B1 (en) 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
AU2010309517B2 (en) * 2009-10-23 2016-10-20 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
ES2364011B1 (es) * 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA2706272C (en) * 2010-06-03 2020-05-05 Accucaps Industries Limited Multi phase soft gel capsules, apparatus and method thereof
JP5829607B2 (ja) * 2010-06-30 2015-12-09 持田製薬株式会社 ω３脂肪酸の配合製剤
NZ744990A (en) 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8715648B2 (en) * 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
JP5876695B2 (ja) 2011-09-29 2016-03-02 森下仁丹株式会社 シームレスカプセルおよびその製造方法
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
HK1206248A1 (en) 2012-05-07 2016-01-08 Omthera Pharmaceuticals Inc. Compositions of statins and omega-3 fatty acids
RU2600804C2 (ru) * 2012-05-22 2016-10-27 Кухниль Фарм. Ко., Лтд. Форма многослойного покрытия фармацевтической композиции для перорального применения, содержащей омега-3 жирную кислоту или ее алкиловый сложный эфир, а также лекарственное средство на основе статина
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
CN102824640A (zh) * 2012-08-06 2012-12-19 济南圣泉唐和唐生物科技有限公司 一种胶囊壳及其制备方法
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
WO2014134466A1 (en) * 2013-03-01 2014-09-04 Amarin Pharmaceuticals Ireland Limited. Co-administration of atorvastatin and ethyl eicosapentaenoic acid or a derivative thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) * 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2015211711B2 (en) * 2014-01-31 2018-05-10 Morishita Jintan Co., Ltd. Orally administered agent for ruminants and ruminant feed containing same
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
EP3160420B1 (en) * 2014-06-26 2019-04-03 R.P. Scherer Technologies, LLC Methods for manufacturing encapsulated granular material, methods for drying coating materials, and fluidized bed dryers
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
CN104940654A (zh) * 2015-06-24 2015-09-30 黄红林 一种葛根胶囊
KR101950907B1 (ko) * 2016-02-05 2019-02-21 한국유나이티드제약 주식회사 지용성 약물 및 방유성 기제가 코팅된 고형제제를 포함하는 경구용 복합제제
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
CN107422021B (zh) * 2017-07-14 2019-11-19 北京朗阅科技有限公司 琼脂糖胶囊及其制备方法与应用
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
WO2019197961A1 (en) * 2018-04-09 2019-10-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of nintedanib esylate
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5488880A (en) * 1977-10-06 1979-07-14 Eru Emu Asoshieito Yuugen Soft capsule
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5953410A (ja) * 1982-09-20 1984-03-28 Fujisawa Pharmaceut Co Ltd 新型ソフトカプセル剤
JPS59157018A (ja) * 1983-02-27 1984-09-06 Furointo Sangyo Kk 新規なる被覆含油カプセル剤形
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
JPS63238015A (ja) * 1987-03-24 1988-10-04 Morishita Jintan Kk 徐放性カプセル製剤
JPH01186815A (ja) * 1988-01-21 1989-07-26 Tokai Kapuseru Kk 軟カプセル剤およびその製造法
JPH01193216A (ja) * 1988-01-29 1989-08-03 Fuji Kapuseru Kk ソフトカプセル及び球状物
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP3159724B2 (ja) * 1991-04-19 2001-04-23 フロイント産業株式会社 シームレスカプセル製造方法および装置
JP3144865B2 (ja) * 1991-12-06 2001-03-12 エーザイ株式会社 軟カプセル剤
JPH0753356A (ja) * 1993-08-16 1995-02-28 Morishita Jintan Kk 酸化され易い油性物質を内容物とするシームレスカプセルおよびその製造方法
JPH0823912A (ja) * 1994-07-19 1996-01-30 Yoshinobu Umeda アシタバ入り食品
US5650232A (en) * 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
GB9916536D0 (en) * 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
WO2003094897A1 (en) * 2002-05-09 2003-11-20 Chugai Seiyaku Kabushiki Kaisha Photostabilized soft capsule
KR100490279B1 (ko) * 2002-07-18 2005-05-17 주식회사 서흥캅셀 구취제거 및 구강 청량 효과를 지닌 젤라틴 연질캅셀제
CA2529735C (en) * 2003-06-20 2012-07-10 Mochida Pharmaceutical Co., Ltd. Eicosapentaenoic acid for preventing or treating varicose veins of lower extremities
JP2005046054A (ja) * 2003-07-29 2005-02-24 Nippon Kayaku Co Ltd ダイエット食品及びダイエット用製剤
JPWO2005102291A1 (ja) * 2004-04-21 2007-08-16 協和醗酵工業株式会社 水溶性活性成分含有シームレスカプセル
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
CA2593768C (en) * 2005-01-04 2014-02-18 Mochida Pharmaceutical Co., Ltd. Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
JP2008534591A (ja) * 2005-03-29 2008-08-28 マクニール−ピーピーシー・インコーポレーテツド 疎水性溶媒内に親水性薬剤を有する組成物
TW200714280A (en) * 2005-06-01 2007-04-16 Takeda Pharmaceuticals Co Novel method of treating hyperlipidemia
JP4327872B2 (ja) 2005-10-07 2009-09-09 トヨタ自動車株式会社 複数枚の回路基板を固定する固定部材とそれを利用したモジュール
EP2526937A1 (en) * 2006-02-07 2012-11-28 Mochida Pharmaceutical Co., Ltd. Composition for prevention of recurrence of stroke
JP4005104B2 (ja) * 2006-02-07 2007-11-07 持田製薬株式会社 脳卒中再発予防用組成物
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
JP2009541433A (ja) * 2006-06-26 2009-11-26 ヴァルファルマ ソチエタ アノニマ オメガポリエン脂肪酸の経口投与のための医薬品の組成物、及び１又はそれ以上の配合禁忌の有効成分、並びにその調剤の工程
WO2008088030A1 (ja) * 2007-01-17 2008-07-24 Mochida Pharmaceutical Co., Ltd. 血栓もしくは塞栓に関連する疾患の予防又は治療用組成物
MY157882A (en) * 2007-06-29 2016-07-29 Takeda Pharmaceutical Seamless capsule

Also Published As

Publication number Publication date
NZ600720A (en) 2012-12-21
AU2008345848A1 (en) 2009-07-16
EA201070835A1 (ru) 2011-02-28
KR20100111292A (ko) 2010-10-14
NZ587019A (en) 2012-07-27
EP2455071A1 (en) 2012-05-23
UA102477C2 (en) 2013-07-10
DOP2010000214A (es) 2010-07-31
JPWO2009087938A1 (ja) 2011-05-26
CN103705486A (zh) 2014-04-09
EP2229939A4 (en) 2011-04-27
ZA201004793B (en) 2011-09-28
EP2229939A1 (en) 2010-09-22
US20100285121A1 (en) 2010-11-11
EP2455070A1 (en) 2012-05-23
NZ600721A (en) 2013-03-28
JP5421126B2 (ja) 2014-02-19
CN101969932A (zh) 2011-02-09
EA201200829A1 (ru) 2012-11-30
CR11625A (es) 2010-09-29
DOP2013000087A (es) 2014-01-31
CO6290641A2 (es) 2011-06-20
UA102478C2 (en) 2013-07-10
CA2711814A1 (en) 2009-07-16
WO2009087938A1 (ja) 2009-07-16
UA100403C2 (en) 2012-12-25
CN103705487A (zh) 2014-04-09
MA32027B1 (fr) 2011-01-03
BRPI0822019A2 (pt) 2015-07-21
MX2010007609A (es) 2010-08-04
IL206791A0 (en) 2010-12-30
EA201200830A1 (ru) 2012-11-30
MY157189A (en) 2016-05-13
DOP2013000085A (es) 2013-06-15
AU2008345848B2 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
ECSP10010395A (es) Formulacion de capsula
NZ590291A (en) Pharmaceutical compositions for treatment of parkinson's disease
ECSP10010514A (es) Formulaciones mejoradas para ingredientes farmaceuticos activos de permeabilidad deficiente
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
CO6731103A2 (es) Formas de dosis de liberación controlada encerradas resistentes a manipulaciones indebidas
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
WO2007143652A3 (en) Chewable soft gelatin capsules
AR082091A1 (es) Composiciones farmaceuticas que comprenden pioglitazona y linagliptina y procedimiento de preparacion
MX2019013095A (es) Formulaciones farmaceuticas de estatinas y acidos grasos omega-3 para encapsulacion.
EA200801926A1 (ru) Таблетки парацетамола с быстрым высвобождением
AR055631A1 (es) Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada
AR076305A1 (es) Composiciones de capsulas biodisponibles de compuesto alfa-(n-sulfonamido) acetamida amorfo
MX344163B (es) Formulaciones farmacéuticas de loratadina para encapsulación y combinaciones de las mismas.
BRPI0509971A (pt) uma forma de dosagem farmacêutica, comprimido e método de preparação
AR061165A1 (es) Formulaciones de liberacion pulsada de fenilefrina y composiciones farmaceuticas
EA201100616A1 (ru) Новые формы применения цинеола
WO2005107709A3 (en) Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
ITMI20050387A1 (it) Nuove capsule di gelatina molle
EA201170880A1 (ru) Таблетка с контролируемым высвобождением с малой дозой активного вещества
AR076916A1 (es) Medicamento a base de calcio y de vitamina d. kit.
TN2010000315A1 (en) Capsule formulation
WO2006122069A3 (en) Formulations of mast cell stabilizing agents for delivery to the colon
AR122036A2 (es) Composiciones farmacéuticas estables para la administración intratecal de arisulfatasa a
AR082906A1 (es) Parches transdermicos de dosis baja con nivel elevado de liberacion de droga
PL400338A1 (pl) Stala doustna postac dawkowania zawierajaca L-jablczan sunitynibu